Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;35(5):584-591.
doi: 10.1111/den.14542. Epub 2023 Mar 30.

Endobiliary radiofrequency ablation for unresectable malignant biliary strictures: Survival benefit perspective

Mingxing Xia  1 , Wenhao Qin  1 , Bing Hu  1
Affiliations
Review

Endobiliary radiofrequency ablation for unresectable malignant biliary strictures: Survival benefit perspective

Mingxing Xia et al. Dig Endosc. 2023 Jul.

Abstract

Endobiliary radiofrequency ablation (RFA) is an emerging technique in recent years for palliating malignant biliary strictures (MBS) unsuitable for surgical resection. To date, many clinical studies have shown good feasibility and safety of this therapy; but controversy exists on whether survival can be improved in patients with advanced MBS. A comprehensive review of the available literature demonstrates that RFA can effectively prolong the overall survival of extrahepatic cholangiocarcinoma (CCA) and ampullary cancer, especially in cases without distant metastasis. However, this topical therapy does not confer a survival benefit in patients with nonprimary bile duct malignancies, such as liver, gallbladder, or pancreatic cancers. Biliary RFA combined with systemic chemotherapy may have a synergistic effect on the outcome of inoperable CCA. Patients with locally advanced tumors rather than distant metastasis might benefit more from this combination therapy.

Keywords: malignant biliary stricture; radiofrequency ablation; survival benefit.

PubMed Disclaimer

References

REFERENCES

    1. Anderson CD, Pinson CW, Berlin J et al. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004; 9: 43-57.
    1. Banales JM, Marin JJG, Lamarca A et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020; 17: 557-88.
    1. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-703.
    1. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-81.
    1. Gao F, Bai Y, Ma SR, Liu F, Li ZS. Systematic review: Photodynamic therapy for unresectable cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2010; 17: 125-31.

LinkOut - more resources